{"version":"1.0","type":"link","title":"Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China.","author_name":"Wu L 외","author_url":"https://prs-insight.online/author/Wu%20L","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/98119","thumbnail_width":1200,"thumbnail_height":630}